ChiCTR2300072971 版本V1.0 版本创建时间2023/06/29 08:47:49 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300072971 

最近更新日期:

Date of Last Refreshed on:

2023-06-29 08:47:28 

注册时间:

Date of Registration:

2023-06-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

Frank’s征及神经丝轻链蛋白预测患者围术期神经认知功能障碍的应用价值探究

Public title:

The clinical application value of Frank's sign and Neurofilament Light Chain levels in predicting perioperative neurocognitive dysfunction

注册题目简写:

English Acronym:

研究课题的正式科学名称:

Frank’s征及神经丝轻链蛋白预测患者围术期神经认知功能障碍的应用价值探究

Scientific title:

The clinical application value of Frank's sign and Neurofilament Light Chain levels in predicting perioperative neurocognitive dysfunction

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈丽丽 

研究负责人:

王胜 

Applicant:

LIli Chen 

Study leader:

Sheng Wang 

申请注册联系人电话:

Applicant telephone:

+86 155 5661 9563

研究负责人电话:

Study leader's
telephone:

+86 191 5600 7726

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

chenlili5601@126.com

研究负责人电子邮件:

Study leader's E-mail:

iamsheng2020@ustc.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

安徽省合肥市庐江路17号

研究负责人通讯地址:

安徽省合肥市庐江路17号

Applicant address:

No.17 Lujiang Road, Hefei City, Anhui Province

Study leader's address:

No.17 Lujiang Road, Hefei City, Anhui Province

申请注册联系人邮政编码:

Applicant postcode:

230001

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

安徽,合肥,中国科学技术大学附属第一医院安徽省立医院麻醉科

Applicant's institution:

Department of Anesthesiology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China

研究负责人所在单位:

安徽,合肥,中国科学技术大学附属第一医院安徽省立医院麻醉科

Affiliation of the Leader:

Department of Anesthesiology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022KY伦审第349号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国科学技术大学附属第一医院医学研究伦理委员会

Name of the ethic committee:

Medical research ethics commitee of the First Affiliated Hospital of University of Science and Technology of China

伦理委员会批准日期:

Date of approved by ethic committee:

2022-12-16 00:00:00

伦理委员会联系人:

胡怡然

Contact Name of the ethic committee:

Yiran Hu

伦理委员会联系地址:

安徽合肥市庐阳区庐江路17号

Contact Address of the ethic committee:

17 Lujiang Road, Luyang District, Hefei, Anhui, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 551 6228 2931

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国科学技术大学附属第一医院安徽省立医院

Primary sponsor:

Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China

研究实施负责(组长)单位地址:

安徽合肥市庐阳区庐江路17号

Primary sponsor's address:

17 Lujiang Road, Luyang District, Hefei, Anhui, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

安徽

市(区县):

合肥

Country:

china

Province:

AnHui

City:

Hefei

单位(医院):

中国科学技术大学附属第一医院安徽省立医院

具体地址:

安徽合肥庐阳区庐江路17号

Institution
hospital:

Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China

Address:

17 Lujiang Road, Luyang District, Hefei, Anhui Province

经费或物资来源:

经费自筹

Source(s) of funding:

self-financing

研究疾病:

折耳征(Frank’s 征)  

Target disease:

Diagonal Earlobe Crease(Frank’s Sign)

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

(1)观察围术期患者折耳征(Frank’s征)、检测患者血浆或血清中神经丝轻链蛋白(NFL)含量,研究折耳征、神经丝轻链蛋白含量是否具有预测围术期神经认知功能障碍的能力 (2)探讨Frank’s征与NFL之间的关系。  

Objectives of Study:

(1)To observe grading of Frank's sign and the concentration of neurofilament light chain protein (NFL) in plasm or serum so as to investigate whether Frank's sign and neurofilament light chain protein levels can predict perioperative delirium and perioperative neurocognitive dysfunction; (2) The correlation between Frank's sign and plasma or serum concentration of NFL was discussed

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)在全身麻醉下接受非心脏非神经外科手术的患者;
(2)美国麻醉医师协会(ASA)分级Ⅰ-Ⅲ级;
(3)年龄60-90岁

Inclusion criteria

(1) Patients undergoing non-cardiac and non-neurosurgical procedures under general anesthesia; (2) American Society of Anesthesiologists (ASA) Grade Ⅰ-Ⅲ; (3) Age 60-90 years old

排除标准:

(1)术前有精神分裂症、癫痫、帕金森症或重症肌无力病史;
(2)MMSE评分:文盲≤19分;受教育水平1-6年≤22分;受教育水平大于6年≤26分;
(3)有严重心肝肺肾功能障碍;
(4)有酗酒史或者目前长期使用镇静药或镇痛药、抗抑郁药;
(5)术前无法沟通(昏迷、重度痴呆、语言障碍);
(6)耳科手术史;
(7)研究者认为不适合入组的其他情况。

Exclusion criteria:

(1) Preoperative history of schizophrenia, epilepsy, Parkinson's disease or myasthenia gravis; (2)MMSE score,illiterate≤19;1-6 years of education years≤22;greater than 7 years≤26(3) severe dysfunction of heart, liver, lung,or kidney function; (4) A history of alcoholism or the current long-term use of sedatives or analgesics, antidepressants; (5) Inability to communicate before surgery (coma, severe dementia, speech disorder); (6) Ear surgery history; (7) Other conditions considered unsuitable for inclusion by the researchers.

研究实施时间:

Study execute time:

From 2023-06-29 00:00:00 To 2023-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-06-29 00:00:00 To 2023-12-30 00:00:00

干预措施:

Interventions:

组别:

根据折耳征(Frank‘s’征)的深浅(0级,I级,IIa级,IIb级,III级)分级

样本量:

400

Group:

Classification according to the death of Frank's sign(Group 0/Group I/Group IIa/Group IIb /Group III)

Sample size:

干预措施:

干预措施代码:

Intervention:

NO

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

安徽 

市(区县):

合肥 

Country:

China

Province:

Anhui

City:

Hefei

单位(医院):

中国科学技术大学附属第一医院安徽省立医院 

单位级别:

三甲 

Institution
hospital:

Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后谵妄

指标类型:

主要指标

Outcome:

postoperative delirium

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生物学标志物

指标类型:

次要指标

Outcome:

Biological marker

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血流动力学

指标类型:

次要指标

Outcome:

Hemodynamics

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

药物用量

指标类型:

次要指标

Outcome:

drug dosage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症

指标类型:

次要指标

Outcome:

postoperative complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后认知功能

指标类型:

主要指标

Outcome:

postoperative cognitive function

Type:

Primary indicator

测量时间点:

测量方法:

相关评估量表

Measure time point of outcome:

Measure method:

指标中文名:

神经丝轻链蛋白浓度

指标类型:

主要指标

Outcome:

Concentration of neurofilaments light chain

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Frank's 征分级

指标类型:

主要指标

Outcome:

Grading of Frank's sign

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不需要

Randomization Procedure (please state who generates the random number sequence and by what method):

Not Required

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

NO

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Do not share metadata

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理由病例记录表、电子采集和管理系统构成

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management consists of case record form and electronic collection and management system in the ResMan Clinical Trial Public Administration Platform.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-06-29 08:47:28